Research programme: Tau protein targeted therapuetics - WaveBreak
Latest Information Update: 28 Aug 2025
At a glance
- Originator WaveBreak
- Class Antidementias; Small molecules
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Tauopathies
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for research development in Alzheimer's-disease in United Kingdom (PO)
- 12 Oct 2023 Early research in Tauopathies in United Kingdom (PO), prior to September 2023 (WaveBreak pipeline, September 2023)
- 09 Dec 2022 Wren Therapeutics plans clinical trials for Neurodegenerative disorders in United Kingdom